ALLSCHWIL/BASEL, SWITZERLAND - 04 May 2010 - At today's Annual General Meeting of Actelion Ltd (SIX: ATLN), shareholders approved all resolutions.
Shareholders approved the annual report, including the financial statements, for the year 2009 and confirmed Ernst & Young to serve as the company's statutory auditors for the year 2010.
The shareholders re-elected three Board members for a term of office of three years. They are Mr. Werner Henrich, Mr. Armin Kessler and Mr. Jean Malo.
The Board comprises a total of ten members: Robert E. Cawthorn (Chairman), Joseph C. Scodari (Vice-Chairman), Jean-Paul Clozel, Werner Henrich, Armin Kessler, Jean Malo, Juhani Anttila, Carl Feldbaum, Michael Jacobi and Elias A. Zerhouni.
The Annual General Meeting of Actelion took place in Basel on Tuesday, 04 May 2010. It was attended by 319 shareholders, representing 45'919'801 shares or 35.52% percent of the total outstanding shares.
###
Actelion Ltd.
Actelion Ltd is a biopharmaceutical company with its corporate headquarters in Allschwil/Basel, Switzerland. Actelion's first drug Tracleer®, an orally available dual endothelin receptor antagonist, has been approved as a therapy for pulmonary arterial hypertension. Actelion markets Tracleer® through its own subsidiaries in key markets worldwide, including the United States (based in South San Francisco), the European Union, Japan, Canada, Australia and Switzerland. Actelion, founded in late 1997, is a leading player in innovative science related to the endothelium - the single layer of cells separating every blood vessel from the blood stream. Actelion's over 2,300 employees focus on the discovery, development and marketing of innovative drugs for significant unmet medical needs. Actelion shares are traded on the SIX Swiss Exchange (ticker symbol: ATLN).
For further information please contact:
Actelion Pharmaceuticals Ltd, Gewerbestrasse 16, CH-4123 Allschwil
Roland Haefeli
Vice President, Head of Investor Relations & Public Affairs
+41 61 565 62 62
+1 650 624 69 36
